While the application of IFN-γ pre-licensed MSCs protected animals from ARS and radiation-induced lethality by day 30, we did not find a protective effect of IFN-γ pre-licensed MSCs in modulating acute GvHD in a model of major histocompatibility complex (MHC)-mismatched HSCT. The gene discussed is IFNG; the disease is graft versus host disease.